Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine polacrilex, quantity: 10 mg (equivalent: nicotine, qty 2 mg) - lozenge - excipient ingredients: indigo carmine aluminium lake; sucralose; sodium bicarbonate; mannitol; magnesium stearate; hypromellose; acesulfame potassium; xanthan gum; sodium carbonate; microcrystalline cellulose; crospovidone; xylitol; calcium hydrogen phosphate; flavour - for the relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. it may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. it should be used as part of a behavioural support programme.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 26.66 mg (equivalent: nicotine, qty 4 mg) - tablet, uncoated - excipient ingredients: xanthan gum; mannitol; sodium carbonate; sodium alginate; aspartame; potassium bicarbonate; magnesium stearate; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine polacrilex, quantity: 10 mg - gum, chewing - excipient ingredients: titanium dioxide; light magnesium oxide; sodium carbonate; hypromellose; xylitol; menthol; sucralose; carnauba wax; acesulfame potassium; sodium bicarbonate; acacia; peppermint oil; polysorbate 80; calcium carbonate; butylated hydroxytoluene; isobutylene/isoprene copolymer; polyisobutylene; polyethylene; polyvinyl acetate; synthetic terpene resin; microcrystalline wax; mono- and di- glycerides; flavour - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitaing smoking cessation in smokers motivated to quit. in smokers unable or not ready to stop smoking abruptly, the inhaler or gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 13.33 mg (equivalent: nicotine, qty 2 mg) - tablet, uncoated - excipient ingredients: mannitol; xanthan gum; potassium bicarbonate; magnesium stearate; sodium carbonate; sodium alginate; aspartame; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine polacrilex, quantity: 20 mg - gum, chewing - excipient ingredients: quinoline yellow aluminium lake; pregelatinised maize starch; acesulfame potassium; polysorbate 80; sodium carbonate; carnauba wax; xylitol; menthol; hypromellose; sucralose; titanium dioxide; peppermint oil; light magnesium oxide; flavour; calcium carbonate; butylated hydroxytoluene; isobutylene/isoprene copolymer; polyisobutylene; polyethylene; polyvinyl acetate; synthetic terpene resin; microcrystalline wax; mono- and di- glycerides - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers unable or not ready to stop smoking abruptly, the gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine polacrilex, quantity: 10 mg - gum, chewing - excipient ingredients: sodium carbonate; pregelatinised maize starch; xylitol; titanium dioxide; sodium bicarbonate; peppermint oil; menthol; acesulfame potassium; light magnesium oxide; sucralose; carnauba wax; polysorbate 80; hypromellose; flavour; calcium carbonate; butylated hydroxytoluene; isobutylene/isoprene copolymer; polyisobutylene; polyethylene; polyvinyl acetate; synthetic terpene resin; microcrystalline wax; mono- and di- glycerides - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit. in smokers unable or not ready to stop smoking abruptly, the inhaler or gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine polacrilex, quantity: 20 mg (equivalent: nicotine, qty 4 mg) - gum, chewing - excipient ingredients: xylitol; light magnesium oxide; peppermint oil; hypromellose; acacia; polysorbate 80; quinoline yellow aluminium lake; titanium dioxide; menthol; sodium carbonate; carnauba wax; acesulfame potassium; sucralose; flavour; calcium carbonate; butylated hydroxytoluene; isobutylene/isoprene copolymer; polyisobutylene; polyethylene; polyvinyl acetate; synthetic terpene resin; microcrystalline wax; mono- and di- glycerides - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine polacrilex, quantity: 20 mg (equivalent: nicotine, qty 4 mg) - gum, chewing - excipient ingredients: carnauba wax; xylitol; quinoline yellow aluminium lake; peppermint oil; acacia; menthol; light magnesium oxide; sodium carbonate; acesulfame potassium; titanium dioxide; calcium carbonate; butylated hydroxytoluene; isobutylene/isoprene copolymer; polyisobutylene; polyethylene; polyvinyl acetate; synthetic terpene resin; microcrystalline wax; mono- and di- glycerides - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thus facilitating smoking cessation in smokers motivated to quit. in smokers unable or not ready to stop smoking abruptly, the inhaler or gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - nicotine polacrilex, quantity: 10 mg (equivalent: nicotine, qty 2 mg) - gum, chewing - excipient ingredients: titanium dioxide; sodium bicarbonate; acacia; menthol; acesulfame potassium; light magnesium oxide; peppermint oil; carnauba wax; xylitol; sodium carbonate; calcium carbonate; butylated hydroxytoluene; isobutylene/isoprene copolymer; polyisobutylene; polyethylene; polyvinyl acetate; synthetic terpene resin; microcrystalline wax; mono- and di- glycerides - for the treatment of tobacco dependence by relieving nicotine craving and withdrawal symptoms thus facilitating smoking cessation in smokers motivated to quit. in smokers unable or not ready to stop smoking abruptly, the inhaler or gum may also be used as part of a smoking reduction strategy as a step towards stopping completely.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

h e b - nicotine (unii: 6m3c89zy6r) (nicotine - unii:6m3c89zy6r) - stop smoking aid